臨床外科72巻9号

2017年09月発行

特集 知っておきたい 乳がん診療のエッセンス

治療編 内科的治療

内分泌療法・分子標的療法（術前・術後・再発）

著者： 中井克也¹ 齊藤光江¹

所属機関： ¹順天堂大学乳腺科

ページ範囲：P.1074 - P.1078

文献概要

【ポイント】
◆閉経前ホルモン受容体陽性乳がんの内分泌治療はタモキシフェンが中心である．転移再発後の内分泌治療法は選択肢が少ない．
◆閉経後ホルモン受容体陽性乳がんの内分泌療法は，術後補助療法としてはアロマターゼ阻害薬が中心となる．転移再発後の内分泌治療としては，アロマターゼ阻害薬のほかにselective estrogen receptor down regulator（SERD）やselective estrogen receptor modulator（SERM）などの選択肢がある．
◆治療選択肢が増えた現状では，転移再発乳がんの治療戦略においてHortobagyiのアルゴリズムにとらわれすぎないことが求められている．

参考文献

1）Perou CM, Sørlie T, Eisen MB, et al：Molecular portraits of human breast tumours. Nature 406：747-752, 2000

2）Dowsett M, Forbes JF, Bradley R, et al：Aromatase inhibitors versus tamoxifen in early breast cancer：patient-level meta-analysis of the randomised trials. Early Breast Cancer Trialists' Collaborative Group（EBCTCG）. Lancet 386：1341-1352, 2015

3）Hackshaw A, Baum M, Fornander T, et al：Long term effectiveness of adjvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst 101：341-349, 2009

4）Cuzick J, Ambroisine L, Davidson N, et al：Use of luteinising hormone releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone receptor positive breast cancer：a meta anlysis of individual patient data from randomized adjuvant traials. Lancet 369：1711-1723, 2007

5）Davies C, Pan H, Godwin J, et al：Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer：ATLAS, a randomised trial. Lancet 381：805-816, 2013

6）Goss PE, Ingle JN, Martino S, et al：Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol 24：355-361, 2013

7）Dowsett M, Cuzick J, Ingle J, et al：Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28：509-518, 2010

8）Goss PE, Ingle JN, Pritchard KI, et al：Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375：209-219, 2016

9）Alba E, Calvo L, Albanell J, et al：Chemotherapy（CT）and hormonotherapy（HT）as neoadjuvant treatment in luminal breast cancer patients：results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol 23：3069-3074, 2012

10）Semiglazov VF, Semiglazov VV, Dashyan GA, et al：Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110：244-254, 2007

11）Ellis MJ, Coop A, Singh B, et al：Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer：evidence from a phase Ⅲ randomized trial. J Clin Oncol 19：3808-3816, 2001

12）Smith IE, Dowsett M, Ebbs SR, et al：Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination：the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen（IMPACT）multicenter double-blind randomized trial. J Clin Oncol 23：5108-5116, 2005

13）Ellis MJ, Suman VJ, Hoog J, et al：Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer：clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031. J Clin Oncol 29：2342-2349, 2011

14）Klijn JG, Beex LV, Mauriac L, et al：Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer：a randomized study. J Natl Cancer Inst 92：903-911, 2000

15）Nishimura R, Anan K, Yamamoto Y, et al：Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen：results of the JMTO BC08-01 phase Ⅱ trial. Oncol Rep 29：1707-1713, 2013

16）Bartsch R, Bago-Horvath Z, Berghoff A, et al：Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. Eur J Cancer 48：1932-1938, 2012

17）Mauri D, Pavlidis N, Polyzos NP, et al：Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer：meta-analysis. J Natl Cancer Inst 98：1285-1291, 2006

18）Robertson JF, Bondarenko IM, Trishkina E, et al：Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer（FALCON）：an international, randomised, double-blind, phase 3 trial. Lancet 388：2997-3005, 2016

19）Baselga J, Campone M, Piccart M, et al：Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366：520-529, 2012

20）Cuzick J, Sestak I, Baum M, et al：Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer：10-year analysis of the ATAC trial. Lancet Oncol 11：1135-1141, 2010

21）Smith IE, Dowsett M, Yap YS, et al：Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea：caution and suggested guidelines. J Clin Oncol 24：2444-2447, 2006